LONGJUMEAU, France, October 22 /PRNewswire-FirstCall/ -- Proteus today announced the completion of a share capital increase reserved for Proteus' industrial partner PCAS. PCAS' stake in Proteus now represents 32% of the issued share capital vs 6% before the increase. Proceeds of this private placement are to be used to accelerate the growth of PROTEUS' PSI and PCAS BIOSOLUTION businesses.
PROTEUS (http://www.proteus.fr) is a biotech company discovering, optimizing, developing and producing new proteins and biotechnological processes for pharmaceuticals, cosmetics, fine chemicals, environmental and other industrial applications. PROTEUS' business is backed by a unique set of technologies, know how and intellectual property portfolio including exclusive resources in natural microbial biodiversity and proprietary technologies for screening, engineering and producing proteins.
PROTEUS offers a range of exclusive solutions for protein manufacturing and engineering through a dedicated business unit "PSI" (Proteus Services for Industry) and through exclusive industrial partnerships. The new proteins and process developed by PROTEUS reinforce the competitive edge and intellectual property position of its clients.
PCAS and PROTEUS already entered into close partnership by forming PCAS BIOSOLUTION, a 50/50 joint venture. The mission of PCAS BIOSOLUTION (http://www.pcas-bio.com) is to design, develop and industrialize new manufacturing routes to produce pharmaceutical intermediates and actives compounds ("API"). The new routes combines chemical processes developed by PCAS and enzymatic catalytic processes ("biocatalysis") developed by PROTEUS.
PCAS thus reinforces its position in "green chemistry", providing its
clients with all the benefits of integrating chemistry and biotechnology.
The new chemo-biocatalytic processes developed at PCAS BIOSOLU
Copyright©2007 PR Newswire.
All rights reserved